Needham Maintains Buy on TransMedics Group, Raises Price Target to $110
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $106 to $110.
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $106 to $110.